Affected by the rapid rise in international commodity prices, increased demand in some domestic industries, and continuous optimization of market competition order, PPI increased by 2.8% year-on-year, with an expansion in growth compared to the previous month.
I expect that China Taiping Insurance's investment in AI will double year-on-year this year. ?Yu Bin revealed. Behind this is a major transformation that insurance companies are undergoing from "+AI" to "AI+". Don't underestimate the subtle differences between the two, as the latter will bring fundamental changes to the logic and development model of the insurance industry. "Yu Bin said that compared to"+AI "which is adding engines to carriages," AI+"is building airplanes.
The mandatory disclosure of ESG by A-share listed companies has completed the "first test". According to statistics from the Industrial Carbon Finance Research Institute, there are a total of 427 companies that are required to disclose their ESG reports for the year 2025 in accordance with exchange regulations. Among them, 18 companies have released independent ESG reports for the first time this year. Fortunately, these "newcomers" have taken a crucial step from 0 to 1 and have established ESG governance structures, incorporating sustainable development into their strategic vision; The worry is that they face the "growing pains" of weak data accumulation and poor historical comparability. Some quantitative indicators only have one year of data, and their continuous disclosure ability and rating improvement still need time to be tested.
By increasing holdings to stabilize the stock price and buy time for pre restructuring, the ultimate goal is to preserve the shell.
Zhao Quanlong frankly stated that after the release of the "Catalogue of Innovative Drugs for Commercial Health Insurance", many insurance companies are exploring the inclusion of new drugs in the claims category as a major selling point of health insurance products. But so far, no health insurance product has been registered and filed in the National Medical Insurance Bureau's big data center. Behind this is the unresolved compliance status of drug discounts, and related health insurance products have always faced risks such as commercial bribery and off balance sheet secrecy, "said Zhao Quanlong.